I’ll spare you the usu­al hype as­so­ci­at­ed with any pub­li­ca­tion’s sub­scrip­tion dri­ve. Suf­fice it to say that Ar­salan Arif and I are a lit­tle over the moon about the ini­tial re­sponse, and we’re in the process of hir­ing for a few enor­mous­ly im­por­tant roles for the team as a re­sult.

The way I had ini­tial­ly en­vi­sioned it, I had thought that the big push would come around the in­di­vid­ual sub­scribers. It was Ar­salan, the plat­form ex­pert here, who blew right past that and set up a com­pelling case for our En­ter­prise sub­scrip­tion for com­pa­nies. Not on­ly did the En­ter­prise subs pro­vide the li­on’s share of the first round of cash, it’s al­so been dri­ving rapid growth in over­all read­er­ship as com­pa­nies spread the word about End­points News and their in­volve­ment as a paid sub­scriber.

Ar­salan is the tac­it tech chief here — I re­main large­ly il­lit­er­ate in that field — and I can’t thank him enough for what he’s done. As a re­sult of his work, most of the largest bio­phar­mas in the world are now on board, along with a lengthy list of biotechs, and we’re work­ing on the rest.

Now that we’ve com­plet­ed the first leg of the En­ter­prise dri­ve, though, I did want to make an­oth­er pitch to you in­di­vid­ual sub­scribers out there who want to sup­port the mis­sion at End­points News. When you don’t have bil­lion­aires writ­ing checks to cov­er op­er­a­tions, this re­mains a key part of our plan for ramp­ing up the ed­i­to­r­i­al and sales teams.

With­out your help, and time and at­ten­tion, we would be look­ing at an ex­treme­ly long run­way to get the group in place.

With your help now, we can stick with the ex­treme­ly short — and fast — track we’ve laid. You can check out the sub­scrip­tion link here be­low.

And thank you.

Get End­points In­sid­er
More De­tails

A small, Santa Ana-based biotech created in 2017 is looking to enter a SPAC deal as it lays out plans to begin trials in its lead cell therapy candidates and bring on new executives.

Graf Acquisition Corp. IV and NKGen Biotech announced Thursday, with few other details, that the two companies signed a non-binding letter of intent to “pursue a business combination.” Graf Acquisition II and III withdrew their IPOs last year.

The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.

The ruxolitinib XR tablets are designed to be taken once a day, whereas Jakafi is indicated for twice daily dosage (although some patients can take it once daily).

According to Incyte, the FDA acknowledged in its complete response letter that the study submitted in the NDA “met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval.”

Cyclerion Therapeutics may have the design of a Phase IIb study ready to go, but it’s scrambling for a way to fund it.

The company said in a press release that it’s “actively evaluating the best combination of capital, capabilities, and transactions available to it to advance the development of zagociguat,” its lead candidate for a rare, genetic mitochondrial disease known as MELAS.

In a separate SEC filing, Cyclerion once again flagged “substantial doubt about (its) ability to continue as a going concern.” As of the end of 2022, it had cash and cash equivalents of only $13.4 million.